Latest / Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
Ultra-rapid insulin, IcoSema advance in type 2 diabetes
Insulin-resistant patients with type 2 diabetes who require high-dose therapy have long lacked a rapid-acting option concentrated enough for compact insulin pumps. New pharmacokinetic data on an ultra-rapid U-500 insulin aspart, alongside additional phase 3 results for a combined once-weekly insulin icodec-semaglutide regimen, both aim to close persistent gaps in insulin delivery for this population. In this episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, reviewed two studies addressing unmet needs in insulin therapy for type 2 diabetes.The investigational…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.